Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RCHOP (zuberitamab) plus chidamide in newly diagnosed AITL with Ig rearrangement
ChiCTR2500106322Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2025
- Modality
- Small Molecules, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hlx01 and tucidinostat in angioimmunoblastic T-cell lymphoma (AITL), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Complete Remission Rate within 6 cycles of chemotherapy. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
hlx01tucidinostat
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on ChiCTR2500106322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106322.